Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 84Neoplasm Metastasis 59Prostatic Neoplasms 57Leukemia, Myeloid, Acute 57Melanoma 49Multiple Myeloma 47Colorectal Neoplasms 44Lung Neoplasms 43Pancreatic Neoplasms 39Carcinoma, Non-Small-Cell Lung 38Lymphoma 37Neoplasms 30Myelodysplastic Syndromes 30Leukemia, Lymphocytic, Chronic, B-Cell 30Squamous Cell Carcinoma of Head and Neck 28Lymphoma, Large B-Cell, Diffuse 25Triple Negative Breast Neoplasms 24Ovarian Neoplasms 24Burkitt Lymphoma 21Rectal Neoplasms 20Lymphoma, Follicular 19Colonic Neoplasms 19Uterine Cervical Neoplasms 18Stomach Neoplasms 18Sarcoma 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Carcinoma, Renal Cell 18Lymphoma, Mantle-Cell 17Glioma 17Head and Neck Neoplasms 16

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Biopsy × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡